Screener
EBIT at other companies
Other financials
Where this comes from
Calculated from Theravance Biopharma’s reported figures.
Plus components not separately reported this period.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026. Open the filing →
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
FAQ
- What is Theravance Biopharma's EBIT?
- Theravance Biopharma (TBPH) reported EBIT of -$9.48M in Q1 2026.
- How has Theravance Biopharma's EBIT changed year-over-year?
- Theravance Biopharma's EBIT increased by 34.3% year-over-year, from -$14.43M to -$9.48M.
- What is the long-term trend for Theravance Biopharma's EBIT?
- Over 4 years (2021 to 2025), Theravance Biopharma's EBIT has grown at a -65.6% compound annual growth rate (CAGR), from -$257.78M to -$3.6M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.
Ask your AI about Theravance Biopharma's ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude